Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Anneloes Noordhof (Leeuwarden, Netherlands), Wouter H. van Geffen (Leeuwarden, Netherlands)

Source: Journal Club 2022
Number: 2

Webcast

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Anneloes Noordhof (Leeuwarden, Netherlands), Wouter H. van Geffen (Leeuwarden, Netherlands). Sotorasib for Lung Cancers with KRAS p.G12C Mutation. Journal Club 2022

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

BEN KALS - 05.12.2023 17:02
I was checking about new developments genital herpes virus then i saw how different persons talks about getting cured from herpes through a particular herbalist called Timothy so decided i Contacted him through his website https://5dc41d5b6d60d.site123.me and he responded with instructions about what he needs to prepare the herbal medication which i did and he sent the herbal meds to me in LA and after drinking the herbal medicine as he instructed i went back to the hospital few months later and the test result shows I'm negative after all the blister symptoms were gone and now I'm completely free of genital Herpes thanks to Dr.Timothy for his medication.
You must Login to comment this presentation.


Related content which might interest you:
Clinical characteristics of 32 patients with BRAF V600E-mutated lung adenocarcinoma
Source: International Congress 2015 – Advances in the therapy of lung cancer
Year: 2015


LSC - 2017 - KRAS & TP53 mutations cause malignant mesothelioma
Source: International Congress 2017 – Pleural disease and mesothelioma: from the bench to the bedside
Year: 2017

EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013


KRAS & TP53 mutations cause malignant mesothelioma
Source: ERS Lung Science Conference 2017
Year: 2017

Equal efficacy of gefitinib in chemonaive lung adenocarcinoma patients with either exon 19 deletion or L858R point mutation
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016


The prognostic value of KRAS mutation according to the gene's
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014

Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013


Mapping of KRAS mutations during chemical carcinogenesis
Source: Virtual Congress 2020 – Inflammatory pathways in chronic airway diseases
Year: 2020


NRAS mutations destine tumor cells to the lungs
Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours
Year: 2015

Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013


Gene expression of EGFR, MINA53,MEN1 and MTOR in NSCLCs
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014


Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement: Analysis of two cases and literature review
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016


LATE-BREAKING ABSTRACT: Treatment efficacy of afatinib vs gefitinib in lung adenocarcinoma with EGFR gene mutation
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016


Prognostic value of EGFR mutation in NSCLC in surgical stage
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014

Are KRAS mutations druggable?
Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine
Year: 2019



Homozygous deletion of PTEN and poor outcomes in EGFR mutant NSCLC patients with gefitinib therapy
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015

Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients
Source: Eur Respir Rev 2014; 23: 390-392
Year: 2014


A detailed immunohistochemical analysis of PI3K/AKT/MTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013

Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014

Gefitinib as first-line treatment for patients with NSCLC with activating EGFR mutationin exons 19 (Del19) or 21 (L858R) in the Czech Republic
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015